Form 4 Filing for Cytokinetics Inc. - Insider Transaction

Robert Arthur Harrington, a director at Cytokinetics Inc., acquired 2,851 shares of Common Stock on May 27, 2026. This transaction was made at a price of $0.0 per share. Following this acquisition, Harrington now owns 21,781 shares of Common Stock directly. Additionally, Harrington was granted 4,301 non-qualified stock options to buy Common Stock on the same date. These options have an exercise price of $77.15 and expire on May 26, 2036. The options were acquired at no cost, and Harrington now holds 4,301 options, all of which are directly owned.